Advertisement
Screener

BRIACELL THERAPEUTICS CORP. (BCTX) Payments to Acquire Investments

2.2 / 5 stars · 22/51 Roast Me

BRIACELL THERAPEUTICS CORP. Payments to Acquire Investments

BRIACELL THERAPEUTICS CORP. (BCTX) reported Payments to Acquire Investments of $260.00 thousand for the 9-month period ending 2026-04-30, per its 10-Q filed 2026-06-09.

Financial Statements › Cash Flow › Investing Activities

us-gaap:PaymentsToAcquireInvestments · last filed 2026-06-09

  • BRIACELL THERAPEUTICS CORP. payments to acquire investments for the quarter ending 2026-04-30 was $95.00K, a 9.52% decline year-over-year.
  • BRIACELL THERAPEUTICS CORP. payments to acquire investments for the quarter ending 2026-01-31 was $90.00K, a 20.00% increase year-over-year.
  • BRIACELL THERAPEUTICS CORP. payments to acquire investments for the quarter ending 2025-10-31 was $75.00K, a 0.00% change year-over-year.
  • BRIACELL THERAPEUTICS CORP. payments to acquire investments for the quarter ending 2025-07-31 was $75.00K.
  • BRIACELL THERAPEUTICS CORP. payments to acquire investments for fiscal 2025 was $330.00K, a 46.67% increase from fiscal 2024.
  • BRIACELL THERAPEUTICS CORP. payments to acquire investments for fiscal 2024 was $225.00K.
Period endPayments to Acquire Investments 3 monthPayments to Acquire Investments 6 monthPayments to Acquire Investments 9 monthPayments to Acquire Investments 12 month
2026-04-30$95.00K
derived: 10-Q 9 month − 10-Q 6 month · filed 2026-06-09
$185.00K
derived: sum of 2 quarters · filed 2026-06-09
$260.00K
10-Q · filed 2026-06-09
$335.00K
derived: sum of 4 quarters · filed 2026-06-09
2026-01-31$90.00K
derived: 10-Q 6 month − 10-Q 3 month · filed 2026-03-10
$165.00K
10-Q · filed 2026-03-10
$240.00K
derived: sum of 3 quarters · filed 2026-03-10
$345.00K
derived: sum of 4 quarters · filed 2026-06-09
2025-10-31$75.00K
10-Q · filed 2025-12-11
$150.00K
derived: sum of 2 quarters · filed 2025-12-11
$255.00K
derived: sum of 3 quarters · filed 2026-06-09
$330.00K
derived: sum of 4 quarters · filed 2026-06-09
2025-07-31$75.00K
derived: 10-K 12 month − 10-Q 9 month · filed 2025-10-16
$180.00K
derived: sum of 2 quarters · filed 2026-06-09
$255.00K
derived: sum of 3 quarters · filed 2026-06-09
$330.00K
10-K · filed 2025-10-16
2025-04-30$105.00K
derived: 10-Q 9 month − 10-Q 6 month · filed 2026-06-09
$180.00K
derived: sum of 2 quarters · filed 2026-06-09
$255.00K
10-Q · filed 2026-06-09
$255.00K
derived: sum of 4 quarters · filed 2026-06-09
2025-01-31$75.00K
derived: 10-Q 6 month − 10-Q 3 month · filed 2026-03-10
$150.00K
10-Q · filed 2026-03-10
$150.00K
derived: sum of 3 quarters · filed 2026-03-10
2024-10-31$75.00K
10-Q · filed 2025-12-11
$75.00K
derived: sum of 2 quarters · filed 2025-12-11
2024-07-31$0.00
derived: 10-K 12 month − 10-Q 9 month · filed 2025-10-16
$225.00K
10-K · filed 2025-10-16
2024-04-30$225.00K
10-Q · filed 2025-06-16

Similar stocks

Stock NameCountryMarket CapPE Ratio
PMGC Holdings Inc. (ELAB)United States$0.037B
Seres Therapeutics, Inc. (MCRB)United States$0.036B-3.45
FILANA THERAPEUTICS, INC. (FLNA)United States$0.038B-1.05
Actinium Pharmaceuticals, Inc. (ATNM)United States$0.038B2.73
MIRA PHARMACEUTICALS, INC. (MIRA)United States$0.036B-4.30
Celularity Inc (CELU)United States$0.038B-0.34
CervoMed Inc. (CRVO)United States$0.038B-1.39
Edesa Biotech, Inc. (EDSA)Canada$0.039B
ROCKWELL MEDICAL, INC. (RMTI)United States$0.035B
Karyopharm Therapeutics Inc. (KPTI)United States$0.039B-0.98